The Valley Desk

NCT02624570 · Expanded access

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Overall registry status No longer available

Conditions Acute Myeloid Leukemia (AML) With, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov